- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Neuropace Inc (NPCE)
Neuropace Inc stock price live, this page displays NASDAQ NPCE stock exchange data. View the NPCE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Neuropace Inc real time stock price chart below.
What Is the Neuropace Inc Stock Price Today?
The Neuropace Inc stock price today is 16.50.
What Is the Stock Symbol for Neuropace Inc?
The stock symbol for Neuropace Inc is ""NPCE.""
What Stock Exchange Does Neuropace Inc Trade On?
Neuropace Inc is listed and trades on the NASDAQ stock exchange.
Is Neuropace Inc a Good Stock to Buy?
Determining whether Neuropace Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NPCE quote. (ISIN: US6412881053)
What Is the Neuropace Inc Stock Price Today?
The Neuropace Inc stock price today is 16.50.
What Is the Stock Symbol for Neuropace Inc?
The stock symbol for Neuropace Inc is ""NPCE.""
What Stock Exchange Does Neuropace Inc Trade On?
Neuropace Inc is listed and trades on the NASDAQ stock exchange.
Is Neuropace Inc a Good Stock to Buy?
Determining whether Neuropace Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NPCE quote. (ISIN: US6412881053)
Fair Value
An estimate of a Neuropace's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.34
16.91
52 wk Range
7.56
18.98
Unusual trading volume
1/2
Fair Value
An estimate of a Neuropace's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.3416.91
52 wk Range
7.5618.98
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NPCE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Neuropace's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
17.50
Upside
+6.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Neuropace Inc Company Profile
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Neuropace Inc SWOT Analysis
Innovative Epilepsy Tech | NeuroPace's RNS System revolutionizes treatment for drug-resistant focal epilepsy, showcasing strong clinical efficacy and market potential |
Financial Momentum | NeuroPace reports impressive revenue growth, with 2025 projections between $93-97 million, reflecting a 16-21% year-over-year increase |
Expanding Horizons | Explore NeuroPace's strategic initiatives, including Project CARE and potential new indications, which could double its addressable market |
Market Valuation | Analyst price targets range from $15 to $20 per share, indicating significant upside potential despite current trading above Fair Value |
Neuropace Inc Earnings Call Summary for Q3/2025
- NeuroPace exceeded Q3 2025 expectations with EPS of -$0.11 (vs -$0.20 forecast) and revenue of $27.4M (30% YoY growth), achieving positive adjusted EBITDA for the first time.
- The company raised full-year revenue guidance to $97-98M (21-23% YoY growth) and increased gross margin guidance to 76-77%, despite stock remaining unchanged at $9.4 post-earnings.
- NeuroPace is strategically focusing on its RNS business (revenue up 31% YoY to $22.6M) while winding down the Dixie product line, targeting PMA supplement submission for IGE indication by year-end.
- Management projects gross margins of at least 80% for 2026 as the company transitions to a pure RNS business, positioning NeuroPace as 'the foundation of the future standard in individualized brain neuromodulation.'
Last Updated: 04/11/2025, 23:58
Read Full TranscriptCompare NPCE to Peers and Sector
Metrics to compare | NPCE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNPCEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −22.9x | −7.6x | −0.6x | |
PEG Ratio | −0.95 | −0.18 | 0.00 | |
Price/Book | 29.7x | 9.1x | 2.6x | |
Price / LTM Sales | 5.8x | 5.3x | 3.3x | |
Upside (Analyst Target) | 9.1% | 23.8% | 40.3% | |
Fair Value Upside | Unlock | −0.9% | 3.9% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.50
(+6.06% Upside)
Earnings
Latest Release
Nov 04, 2025
EPS / Forecast
-0.11 / -0.20
Revenue / Forecast
27.40M / 24.31M
People Also Watch
FAQ
What Stock Exchange Does Neuropace Trade On?
Neuropace is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Neuropace?
The stock symbol for Neuropace is "NPCE."
What Is the Neuropace (NPCE) Afterhours Price Today? (Afterhours variable test: 16.46) Current Date: 27 Nov 2025
After hours price: 16.46. After hours price change (units): -0.04. Price change percentage: -0.24%
What Is the Neuropace Market Cap?
As of today, Neuropace market cap is 549.58M.
What Is Neuropace's Earnings Per Share (TTM)?
The Neuropace EPS (TTM) is -0.75.
When Is the Next Neuropace Earnings Date?
Neuropace will release its next earnings report on 09 Mar 2026.
From a Technical Analysis Perspective, Is NPCE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Neuropace Stock Split?
Neuropace has split 0 times.
How Many Employees Does Neuropace Have?
Neuropace has 209 employees.
What is the current trading status of Neuropace (NPCE)?
As of 27 Nov 2025, Neuropace (NPCE) is trading at a price of 16.50, with a previous close of 16.70. The stock has fluctuated within a day range of 16.34 to 16.91, while its 52-week range spans from 7.56 to 18.98.
What Is Neuropace (NPCE) Price Target According to Analysts?
The average 12-month price target for Neuropace is USD17.5, with a high estimate of USD20 and a low estimate of USD15. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +6.06% Upside potential.
What Is the NPCE After Hours Price?
NPCE's last after hours stock price is 16.46, the stock has decreased by -0.04, or -0.24%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.